KI
Ing Lorenzini, Kuntheavy
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients | Viruses | 2024 | 121 | 74 | |||
| Practice of CYP450 genotyping and phenotyping in children in a real-life setting | Frontiers in pharmacology | 2023 | 74 | 118 | |||
| Relapses of Immune Thrombocytopenia after the Second and Booster Doses of BNT162b2 Vaccine | Acta haematologica | 2023 | 65 | 69 | |||
| A severe case of rhabdomyolysis after Moderna mRNA anti‐COVID ‐19 vaccine with a literature review | Clinical case reports | 2023 | 143 | 82 | |||
| Opioid‐related adverse drug reactions in patients visiting the emergency division of a tertiary hospital | Pharmacology research & perspectives | 2022 | 150 | 72 | |||
| Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia | JAMA | 2022 | 169 | 0 | |||
| Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trial | Clinical and translational science | 2022 | 148 | 97 | |||
| Case Report: Opioid Use Disorder Associated With Low/Moderate Dose of Loperamide in an Intellectual Disability Patient With CYP3A and P-Glycoprotein Reduced Activity | Frontiers in psychiatry | 2022 | 99 | 97 | |||
| Fracture risk following an atypical femoral fracture | Journal of bone and mineral research | 2022 | 266 | 259 | |||
| CYP450 Genotype-Phenotype Concordance Using the Geneva Micrococktail in a Clinical Setting | Frontiers in pharmacology | 2021 | 277 | 215 | |||
| Various approaches to postmarketing drug safety monitoring | 2021 | 259 | 570 | ||||
| Outcomes of drug exposition during pregnancy: Analysis from a teratology information service | European Journal of Obstetrics, Gynecology, and Reproductive Biology | 2020 | 275 | 4 | |||
| Direct-acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV-infected patients | Liver International | 2020 | 347 | 266 | |||
| Automatic Classification of Discharge Letters to Detect Adverse Drug Reactions | Studies in Health Technology and Informatics | 2020 | 464 | 161 | |||
| Evaluation of Phenotypic and Genotypic Variations of Drug Metabolising Enzymes and Transporters in Chronic Pain Patients Facing Adverse Drug Reactions or Non-Response to Analgesics: A Retrospective Study | Journal of Personalized Medicine | 2020 | 350 | 91 | |||
| Importance et particularités de la pharmacovigilance en pédiatrie | Revue médicale suisse | 2019 | 416 | 392 | |||
| Severe and persistent morphine-induced respiratory depression associated with ATP-Binding Cassette Subfamily B Member 1 and catechol-O-methyltransferase genetic defects: A case report | European Journal of Anaesthesiology | 2018 | 443 | 322 | |||
| Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study | Pharmacological research | 2017 | 659 | 172 | |||
| "Late" Withdrawal Syndrome after Carbamazepine In Utero Exposure in a CYP2C9 Slow Metabolizer Newborn | Frontiers in Pharmacology | 2017 | 633 | 212 | |||
| Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study | Clinical microbiology and infection | 2017 | 636 | 4 | |||
| Maternal Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes Syndrome and Neonatal Magnesium Toxicity: A Case Report | Gynecology and Obstetrics | 2017 | 399 | 252 | |||
| Meta-xylene: identification of a new antigenic entity in hypersensitivity reactions to local anesthetics | Journal of allergy and clinical immunology. In practice | 2016 | 659 | 1 | |||
| Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect | Frontiers in pharmacology | 2016 | 506 | 221 | |||
| Severe Vincristine-Induced Neuropathic Pain in a CYP3A5 Nonexpressor With Reduced CYP3A4/5 Activity: Case Study | Clinical therapeutics | 2016 | 554 | 2 | |||
| Cannabinoïdes médicaux dans les douleurs chroniques : aspects pharmacologiques | Revue médicale suisse | 2015 | 689 | 5 | |||
| Is pholcodine a dangerous cough suppressant? | European journal of anaesthesiology | 2015 | 625 | 1 | |||
| Reversible ventricular arrythmia induced by dasatinib | Clinical case reports | 2013 | 655 | 216 | |||
| Applications of CYP450 Testing in the Clinical Setting | Molecular diagnosis & therapy | 2013 | 765 | 857 | |||
| Quel programme informatique de détection des interactions médicamenteuses néfastes ? | Revue médicale suisse | 2012 | 971 | 946 | |||
| Validation of the simplified UVB model to assess the pharmacodynamics of analgesics in healthy human volunteers | Chimia | 2012 | 798 | 1,138 | |||
| Pharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. A minireview | Basic & clinical pharmacology & toxicology | 2012 | 650 | 682 | |||
| Fracture atypique du fémur sous bisphosphonates, un effet indésirable à ne pas manquer | Revue médicale suisse | 2012 | 612 | 0 | |||
| Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta--a case report | Acta orthopaedica | 2012 | 672 | 284 | |||
| Aspects pharmacodynamiques et pharmacocinétiques d'une combinaison de paracétamol et d'AINS | 2011 | 1,662 | 12 | ||||
| A randomized, controlled trial validates a peripheral supra-additive antihyperalgesic effect of a paracetamol-ketorolac combination | Basic & clinical pharmacology & toxicology | 2011 | 675 | 0 | |||
| ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia | Pharmacogenomics | 2011 | 947 | 6 | |||
| Two-dimensional liquid chromatography-ion trap mass spectrometry for the simultaneous determination of ketorolac enantiomers and paracetamol in human plasma: application to a pharmacokinetic study | Journal of chromatography | 2009 | 558 | 0 | |||
| Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital | Drug safety | 2009 | 618 | 0 |
